Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00424 | perfluorophenyl 3-(2-(2-(2-(cyclooct-2-ynyloxy)acetamido)ethoxy)ethoxy)propanoate | |
| Perfluorophenyl 3-(2-(2-(2-(cyclooct-2-ynyloxy)acetamido)ethoxy)ethoxy)propanoate is a widely used biomedical agent. Due to its special chemical properties and composition, it represents a typical tool in the biomedical field. This exquisite entity has demonstrated its potential as a powerful drug, adept at effectively targeting unique cellular pathways and receptors responsible for treating a variety of diseases. | Inquiry | |
| BADC-00425 | 2,5-dioxopyrrolidin-1-yl 3-(2-(2-(2-(cyclooct-2-ynyloxy)acetamido)ethoxy)ethoxy)propanoate | |
| 2,5-dioxopyrrolidin-1-yl 3-(2-(2-(2-(cyclooct-2-ynyloxy)acetamido)ethoxy)ethoxy)propanoate is a pharmaceutical compound widely used in the biomedical field. Its powerful medicinal properties are effective against drug-resistant strains, especially in overcoming Gram-positive infections. | Inquiry | |
| BADC-00426 | Perfluorophenyl 2-(cyclooct-2-ynyloxy)acetate | 886209-60-5 |
| Perfluorophenyl 2-(cyclooct-2-ynyloxy)acetate is a cleavable ADC junction bridge for the synthesis of antibody drug conjugates (ADCs). It is a chemical compound used in click chemistry and bioconjugation applications. It features a cyclooctyne moiety, which is a reactive cyclic alkyne with a strained ring structure, making it highly reactive in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions. The O-PFP (pentafluorophenyl) ester group is a reactive functional group that facilitates the attachment of this molecule to other biomolecules or surfaces. This compound is often used for labeling, imaging, or creating bioconjugates in chemical biology and drug development. | Inquiry | |
| BADC-00427 | 2,5-dioxopyrrolidin-1-yl 2-(cyclooct-2-ynyloxy)acetate | 1425803-45-7 |
| 2,5-dioxopyrrolidin-1-yl 2-(cyclooct-2-ynyloxy)acetate is a promising biomedical chemical used in the treatment of various diseases. It exhibits potential therapeutic effects against inflammation, cancer, and microbial infections. This compound acts by targeting specific receptors and pathways, modulating cellular processes, and promoting desired therapeutic outcomes. Further research on its pharmacological properties and clinical applications shows immense potential for disease management and improved patient outcomes. | Inquiry | |
| BADC-00428 | 2,5-dioxopyrrolidin-1-yl 3-(2-(2-undec-10-ynamidoethoxy)ethoxy)propanoate | 1006592-59-1 |
| 2,5-dioxopyrrolidin-1-yl 3-(2-(2-undec-10-ynamidoethoxy)ethoxy)propanoate is a small molecule compound. It has attracted great attention in the biomedical field because of its remarkable ability to fight bacterial infections. Its unparalleled efficacy in precisely targeting drug delivery systems and amplifying therapeutic effects has been extensively documented through comprehensive research. | Inquiry | |
| BADC-00429 | 2,5-dioxopyrrolidin-1-yl 7,10,13-trioxa-4-azahexadec-1-yn-16-oate | 1214319-94-4 |
| 2,5-Dioxopyrrolidin-1-yl 7,10,13-trioxa-4-azahexadec-1-yn-16-oate is a compound widely employed within the biomedical sector and exhibits promising implications for diverse maladies and ailments. Owing to its exceptional ability to target distinct drug receptors and pathways, this chemical entity unveils itself as a prospective therapeutic agent. | Inquiry | |
| BADC-00430 | Propargyl-PEG4-NHS ester | 1428629-70-2 |
| Inquiry | ||
| BADC-00431 | 2,5-dioxopyrrolidin-1-yl 17-oxo-4,7,10,13,19-pentaoxa-16-azadocos-21-yn-1-oate | |
| 2,5-dioxopyrrolidin-1-yl 17-oxo-4,7,10,13,19-pentaoxa-16-azadocos-21-yn-1-oate is a bioactive compound. Its extraordinary power lies in its ability to selectively manipulate protein interactions to modulate complex cellular machinery. | Inquiry | |
| BADC-00432 | Propargyl-O-C1-amido-PEG3-C2-NHS ester | 2101206-78-2 |
| Propargyl-O-C1-amido-PEG3-C2-NHS ester is a non-cleavable 3-unit PEG linker that can be used to synthesize antibody-conjugated drugs (ADCs). | Inquiry | |
| BADC-00433 | 2,5-dioxopyrrolidin-1-yl 11-oxo-4,7,13-trioxa-10-azahexadec-15-yn-1-oate | |
| 2,5-dioxopyrrolidin-1-yl 11-oxo-4,7,13-trioxa-10-azahexadec-15-yn-1-oate is a bioactive compound. It has therapeutic potential in biomedicine against a variety of diseases, including cancer and inflammatory diseases. This compound has considerable antitumor properties and therefore holds promise as a viable intervention. Additionally, preclinical studies have revealed its anti-inflammatory properties. | Inquiry | |
| BADC-00434 | 5-hexynoic NHS ester | 906564-59-8 |
| Inquiry | ||
| BADC-00435 | 4-pentynoic acid succinimidyl ester | 132178-37-1 |
| 4-Pentynoic acid succinimidyl ester is a biomedicine product extensively utilized in the pharmaceutical industry. It acts as a pivotal reagent facilitating the derivatization of diverse drugs and molecules. This compound has the ability to form stable amide bonds and is an important tool in drug discovery and bioconjugation research. The remarkable versatility of this compound fuels the advancement of targeted therapeutic approaches, diagnostic instruments, and drug conveyance mechanisms. | Inquiry | |
| BADC-00436 | Mal-Ph-CONH-PEG4-NHS ester | 1263044-88-7 |
| Mal-Ph-CONH-PEG4-NHS ester is a non-cleavable 4-unit PEG ADC linker that is used in the synthesis of antibody-conjugated drugs (ADCs). | Inquiry | |
| BADC-00437 | 2,5-dioxopyrrolidin-1-yl 19-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-19-oxo-4,7,10,13,16-pentaoxanonadecan-1-oate | 1232769-29-7 |
| 2,5-dioxopyrrolidin-1-yl 19-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-19-oxo-4,7,10,13,16-pentaoxanonadecan-1 -oate is an innovative biomedical chemical. Utilizing its unique chemical composition, it actively disrupts malignant molecular pathways to prevent tumor proliferation. Its superb targeted delivery capabilities act as a catalyst, amplifying the therapeutic effects and propelling it to the forefront of promising targeted cancer treatment candidates. | Inquiry | |
| BADC-00438 | MAL-Di-EG-OPFP | 1347750-81-5 |
| MAL-Di-EG-OPFP is a fluorescent dye widely used in the biomedical field and has extensive uses in biomolecular labeling and research on complex cellular mechanisms. This exceptional product significantly contributes to the advancement of pharmacological breakthroughs while addressing critical needs in disease diagnosis, including cancer and neurodegenerative diseases. | Inquiry | |
| BADC-00439 | MC-PEG2-C2-NHS ester | 1263044-56-9 |
| MC-PEG2-C2-NHS ester is a non-cleavable 2-unit PEG linker that is used in the synthesis of antibody-conjugated drugs (ADCs). | Inquiry | |
| BADC-00440 | Maleimide-NH-PEG10-CH2CH2COONHS Ester | 1137109-22-8 |
| Maleimide-NH-PEG10-CH2CH2COONHS Ester is a versatile bioactive ester that can be used to develop targeted drug delivery systems. It acts as a linker to bind drugs or imaging agents to targeting molecules, facilitating their selective delivery to specific cells or tissues. In addition, it can be used in the development and synthesis of cancer treatment drugs. | Inquiry | |
| BADC-00441 | Mal-PEG8-NHS | 756525-93-6 |
| Mal-PEG8-NHS is a biochemical product widely used in drug delivery and in-depth biopharmaceutical research. As a polyethylene glycol (PEG) derivative conjugated to a maleimide moiety, it is widely used in drug delivery systems and bioconjugation. | Inquiry | |
| BADC-00442 | Mal-PEG6-NHS | 1137109-21-7 |
| Mal-PEG6-NHS is a widely employed biomedical reagent within drug delivery systems and bioconjugation processes. Embedding a maleimide moiety facilitates precise targeting, while supplemented with a polyethylene glycol (PEG) spacer, it accomplishes elevated solubility and biocompatibility. Resultantly, Mal-PEG6-NHS serves as a pivotal constituent enabling the formulation of therapeutic agents to combat a spectrum of illnesses encompassing cancer, cardiovascular ailments, and inflammatory disorders. | Inquiry | |
| BADC-00443 | Mal-PEG5-NHS | 1315355-92-0 |
| Mal-PEG5-NHS is a biomedical product that assumes a pivotal role in drug conjugation and protein modification. Its exceptional reactivity as a linker fosters targeted drug delivery, thereby ramping up therapeutic efficacy to unprecedented levels. | Inquiry |
